🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Rani Therapeutics Holdings, Inc. RANI PHARMA

Healthcare · Biotechnology · United States
https://www.ranitherapeutics.com
Company Profile ↓
$0.87
+65.25% 1Y
Mkt Cap$100.42M
P/E-6.69
P/B2.47
52W High$2.85
52W Low$0.46
Book Value$0.35
EPS (TTM)$-0.13

Company Overview

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat rheumatoid arthritis; RT-116 which is in discovery stage for the treatment of obesity; RT-117 for rare diseases; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The company has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity; Chugai Pharmaceutical Co., Ltd. to commercialize the Chugai Product combining Chugai's Compound, which is in development for hemophilia, and the RaniPill HC oral delivery device for use in humans; and has a research and development collaboration with PegBio Co., Ltd. to expand obesity pipeline across multiple novel candidates. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 37.1% CAGR over the past five years.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.07.

Recent Developments

  • Dec 2025 Revenue of $1.63M (+58.9% YoY); net profit $-29.67M.
  • Trailing 12 Months Year-on-year growth — revenue +893.0%.
  • 5-Year Trend Long-term compounding — revenue CAGR 37.1%.

Growth & Price Performance

Compounded Sales Growth

5 Years:37.12%
1 Year:893.00%

Stock Price Performance

1 Year:+65.25%
6 Months:-36.78%
3 Months:+3.87%
1 Month:+10.16%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 17% of range
$0.46 $2.85
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMABelow
  • RSI (14)56.68 · Neutral
Price Performance
1M+10.16%
3M+3.87%
6M-36.78%
1Y+65.25%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 37.1% over 5 years.

CONS

  • Trading 69.4% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-6.69
Industry PE
24.83
Forward P/E
-4.58
PEG Ratio
-
Book Value
$0.35
Price to Book
2.47
P/S
24.84
EV/EBITDA
-1.81
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
37.12%
Profit 5Y
-
Revenue (YoY)
893.00%
Earnings (YoY)
-

Profitability & Returns

ROCE
-83.37%
ROE
-
ROA
-52.99%
Profit Margin
0.00%
Op Margin
-
Gross Margin
100.00%
EPS (Latest Qtr)
$-0.04
EPS (TTM)
$-0.13

Balance Sheet & Liquidity

Debt/Equity
0.07
Quick Ratio
5.23
Current Ratio
5.31
Debt
$3.55M
Total Assets
$51.88M
Current Assets
$47.09M
Working Capital
$40.65M

Ownership

Promoter Holding
4.91%
Chg in Prom Hold
-0.14%
FII / Inst Holding
46.80%
Chg in FII Hold
-0.00%

Financial Snapshot

Enterprise Value
$100.42M
Total Revenue (TTM)
$4.88M
EBITDA
$-32.24M
Free Cash Flow
$-8.87M
Operating Cash Flow
$-20.29M
Shares Outstanding
115.42M
Gross Margin
100.00%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 RANI Rani Therapeutics Holdings, Inc. PHARMA 0.87 -6.69 $100.42M 0.00% -83.37% - 37.12% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -60.00K108.00K756.00K1.96M0-00---000172.00K001.46M1.71M
Cost of Revenue --------------------
Gross Profit --------------------
Operating Expenses ---------------12.19M10.51M7.26M10.00M10.05M
Operating Income --3.39M-2.83M-5.20M-5.26M-27.78M-13.78M-15.85M-16.34M-16.52M-18.29M-17.86M-14.03M-12.52M-11.80M-12.01M-10.51M-7.26M-8.54M-8.34M
EBITDA ----------------11.54M-10.11M-6.97M-8.54M-7.77M
Interest Expense ---------------943.00K877.00K725.00K347.00K88.00K
Pretax Income ----------------12.74M-11.22M-7.91M-9.07M-8.02M
Tax Provision --------------------
Net Income -5.35M-2.71M-2.88M-5.60M-5.49M-3.14M-6.22M-7.62M-7.96M-8.37M-9.30M-9.20M-7.48M-6.80M-6.78M-7.26M-6.69M-5.41M-10.30M-7.03M
Diluted EPS ------0.160.290.310.33-0.33-0.37-0.36-0.29-0.26-0.24-0.22-0.18-0.12-0.07-0.04
R&D Expense -2.56M2.09M3.35M3.76M11.96M7.59M9.53M9.10M9.71M11.09M11.22M7.59M6.12M6.17M6.57M5.50M3.22M-5.16M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 462.00K-001.03M1.63M
Cost of Revenue ------
Gross Profit ------
Operating Expenses --63.45M66.10M50.63M39.94M
Operating Income -16.54M--63.45M-66.10M-49.60M-38.31M
EBITDA ---61.66M-61.98M-50.52M-37.16M
Interest Expense --1.07M5.08M5.03M2.89M
Pretax Income ---63.27M-67.88M-56.58M-40.95M
Tax Provision -41.00K70.00K0--
Net Income ---30.59M-33.97M-30.02M-29.67M
Diluted EPS ---1.28-1.33-1.05-0.45
R&D Expense 12.04M26.48M36.61M39.62M26.68M20.20M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets 79.42M-108.03M57.92M36.63M58.62M
Current Assets --100.92M50.85M29.74M53.32M
Cash & Equivalents 73.06M-27.01M5.86M3.76M18.62M
Inventory ------
Receivables ----02.04M
Total Liabilities 8.04M-34.02M32.47M33.14M17.11M
Current Liabilities 5.31M-4.82M7.99M19.89M12.67M
Long Term Debt 2.41M-29.15M24.48M9.61M-
Total Debt --30.21M30.10M29.71M4.32M
Total Equity -113.34M-36.85M12.87M1.99M33.01M
Shares Outstanding --25.30M26.04M33.43M97.62M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -14.96M--46.52M-51.24M-35.50M-18.71M
Investing Cash Flow -1.20M--72.44M29.86M19.81M-7.03M
Financing Cash Flow 72.68M-29.00M233.00K13.59M40.30M
Capital Expenditure -1.20M--1.62M-1.23M-268.00K-88.00K
Free Cash Flow -16.16M--48.13M-52.47M-35.76M-18.80M
Net Change in Cash ---89.95M-21.14M-2.10M14.56M

Ratios (Annual)

Figures in %.

Metric Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ------
Operating Margin % -3,581.0%----4,824.9%-2,346.0%
Net Margin % -----2,920.0%-1,817.1%
ROE % ---83.0%-264.0%-1,506.9%-89.9%
ROCE % -22.3%--61.5%-132.4%-296.2%-83.4%

Shareholding Pattern

Insiders
4.91%
Institutions
46.80%
Public Float
49.22%

Top Institutional Holders

#Holder% HeldSharesValue
1 Samsara BioCapital, LLC 8.98% 10.37M $8.94M
2 RA Capital Management, L.P. 7.36% 8.50M $7.33M
3 AWM Investment Company, Inc. 6.50% 7.50M $6.46M
4 Vanguard Capital Management LLC 3.95% 4.56M $3.93M
5 SymBiosis Capital Partners, LLC 3.18% 3.67M $3.16M
6 Longaeva Partners L.P. 2.02% 2.33M $2.01M
7 Polar Asset Management Partners Inc. 2.01% 2.32M $2.00M
8 Siren, L.L.C. 1.73% 2.00M $1.72M
9 Heights Capital Management, Inc 0.81% 934.58K $805.61K
10 Geode Capital Management, LLC 0.77% 890.62K $767.71K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for RANI

Google News ue, 08 Sep 2026

Rani Therapeutics will appear in New York on Sept. 10 and 14 - Stock Titan

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxPcDkxdGE3ZGVtY3VFUlIwTmh3czdQQnNaMkU0bThVdGQ3dUhjVmk4OXVtRTJWdDNJV0Q3RmtSakNFWkZpczR2R2sxWUpwSXFZb1FSSUJEUElfa0ctMDlOZ1FuMExuMnVPdC1UTklZazZGQkM4VVdBWWNRZGp0TXJ0VXdkekpuX0lnbTRIYj…

Google News Sat, 05 Sep 2026

Rani Therapeutics Holdings Stock Price Forecast. Should You Buy RANI? - StockInvest.us

<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTE5HRlhqU2pzbWpHLUYwTFJ5NGFpbldiR1k4cDNJMGNBeGg1Zkt3NHkxWU5FeHZrcDFYZVZqYzBCVENlWGV6dVhOWg?oc=5" target="_blank">Rani Therapeutics Holdings Stock Price Forecast. Should You Buy RANI?…

Google News hu, 20 Aug 2026

We're Hopeful That Rani Therapeutics Holdings (NASDAQ:RANI) Will Use Its Cash Wisely - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi9AFBVV95cUxPcDc2SmN2QmZjblZmV1h1eUFDcWhsaGp0Rkt3enVnazJWZHhUNk1KUmNlQXoxU0RKWDdyTk9WLVZmLW5rbG5jaS1tdjVBRVV6WGtHZWN2d3RKSjlnU3V0UVlhNDlnN01EeW9qd3dUNDdmLWx4MXduOHRocUFxM1N4TDg0YjNJU29IVkxJeH…

Google News Wed, 22 Jul 2026

$RANI stock is up 30% today. Here's what we see in our data. - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxPakdJWWdmTFFYTHYzWGpLT09mUC12UjFZQmxUc0xMOGc1S2lqdmRaOUdQaDUzbmtqaG9OVk5QdUY5V0tid3d6dFFTVnFHOEQycUhtT29qNHpka0gtZVZYMjFxcmFXS003RlBEMFBrTTh0WjRxQXVTZ2ZrTHFFTUcwMzVKYnRHWURvNDBka0…

Google News Fri, 24 Jul 2026

Rani Therapeutics director Mir A Imran buys $24,839 in stock - Investing.com

<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxQazgtRm1oV0VmVGRjTDVkQXAzNVFVU1pscFhhVFlzOTh4emRJU3pLemZWQWF0SXZzSWZMMUpBLVc3VmVLazhRS2VOX3JsV25hQ2JNMll3eEVLZ0tROTNIYzVrVFFFbTJDWkJucXc2QThxd2VseUVMTGMycWlkZHVkNGVhdWhwXzJ6XzBpcn…

Google News ue, 26 May 2026

RANI - Finviz

<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE5LMVlpNl83WjU2WkUtM21qUzZ0VWdfLXFEcHZQakp1YWZleUlSdklQdC03N2dPR196bXlVR2FQV2c3OHBHNlE?oc=5" target="_blank">RANI</a>&nbsp;&nbsp;<font color="#6f6f6f">Finviz</font>…

RANI — Frequently Asked Questions

What is the current share price of Rani Therapeutics Holdings, Inc. (RANI)?

As of 2026-09-19 21:16 PDT, Rani Therapeutics Holdings, Inc. (RANI) trades at $0.87 on NasdaqGM. Its 52-week range is $0.46 to $2.85.

What is the market capitalisation of RANI?

Rani Therapeutics Holdings, Inc. (RANI) has a market capitalisation of $100.42M on NasdaqGM.

What is the P/E ratio of RANI?

RANI trades at a trailing price-to-earnings (P/E) ratio of -6.69. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.47.

Is RANI a good stock to buy?

This page provides a data-driven analysis of Rani Therapeutics Holdings, Inc. (RANI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space